summary
Introduced
06/13/2019
06/13/2019
In Committee
06/14/2019
06/14/2019
Crossed Over
Passed
Dead
12/31/2020
12/31/2020
Introduced Session
116th Congress
Bill Summary
To amend title XIX of the Social Security Act to exclude authorized generic drugs from calculation of the average manufacturer price for purposes of the Medicaid drug rebate program, and for other purposes. This bill alters certain requirements and definitions under the Medicaid Drug Rebate Program relating to rebate calculations. Specifically, the bill repeals the requirement that drug manufacturers include the prices of certain authorized generic drugs when determining the average manufacturer price (AMP) of brand-name drugs (also known as a "blended AMP"), and excludes manufacturers from the definition of "wholesalers" for purposes of rebate calculations.
AI Summary
This bill, the Fair and Accurate Medicaid Pricing Act of 2019 (also known as the Fair AMP Act), amends the Medicaid Drug Rebate Program to exclude authorized generic drugs from the calculation of the average manufacturer price (AMP) of brand-name drugs. Additionally, the bill excludes drug manufacturers from the definition of "wholesalers" for the purposes of rebate calculations. These changes are intended to address issues related to the pricing and rebates of certain pharmaceutical products under the Medicaid program.
Committee Categories
Business and Industry, Health and Social Services
Sponsors (4)
Last Action
Referred to the Subcommittee on Health. (on 06/14/2019)
Official Document
bill text
bill summary
Loading...
bill summary
Loading...
bill summary
| Document Type | Source Location |
|---|---|
| State Bill Page | https://www.congress.gov/bill/116th-congress/house-bill/3276/all-info |
| BillText | https://www.congress.gov/116/bills/hr3276/BILLS-116hr3276ih.pdf |
| Bill | https://www.congress.gov/116/bills/hr3276/BILLS-116hr3276ih.pdf.pdf |
Loading...